The combined therapy increased median survival 70-130% compared to immunotherapy alone.
总的来说,A组的中位生存期是30.9个月,B组的为21个月。
Overall, the median survival time for patients in Group A was 30.9 months compared with 21 months for those in Group B.
若不进行治疗,WAS患者的中位生存期仅为14岁,干细胞移植治疗具有显著的死亡和发病风险。
Without treatment, the median survival for WAS patients is 14 years of age and treatment with stem cell transplant carries significant risk of mortality and morbidities.
不使用这两种药物的患者的中位生存期也为3.1年。
The median survival for those who did not use either drug was also 3.1 years.
这是首次看到广泛期小细胞肺癌患者的中位生存期超过一年。
This isFor the first time, the median survival of patients with extensive-stage small-cell lung cancer was more than one year.
他们的中位生存期为48个月,而所有患者的中位生存期为16.75个月。
The median survival of these patients was 48 months, while the median survival of all patients on the registry was 16.75 months.
期临床试验结果也确认,它能够显着提高患者的中位生存期。
Phase 3 clinical trial resultsalso confirmed that it can significantly improve the median survival of patients.
在常规治疗的情况下,这些患者的预期中位生存期将不到1年。
With conventional treatment, the expected median survival for these individuals would be less than a year.
脑转移的存在通常会使患者的中位生存期缩短至不到8个月。
The presence of brain metastases often reduces median survival to less than eight months.
尽管报道的中位生存期是18到24个月,但一些患者可以活得更长。
Although median survival has been reported to be 18 to 24 months, some patients experience….
例如,如果癌症患者“经治疗的中位生存期小于24个月”且符合其他标准,那么他们将被拒绝接受治疗。
For example, patients with cancer are deniedtreatment if they have a"less than 24 months median survival with treatment" and fit other criteria.
尽管报道的中位生存期是18到24个月,但一些患者可以活得更长。
Although median survival has been reported to be 18 to 24 months, some patients experience long-term survival..
的人没有这些因素;他们的中位生存期为18.5个月。
Eleven percent had none of the factors, and their median survival was 18.5 months.
在常规治疗的情况下,这些患者的预期中位生存期将不到1年。
With conventional treatment, their expected median survival would be less than a year.
复发或难治性(R/R)高风险神经母细胞瘤是最致命的儿童癌症之一,目前的中位生存期约为1-3年。
R/R high risk neuroblastoma is one of the deadliest types of childhood cancer andthe current median survival is around 1-3 years.
淋巴结阳性R(un)患者的中位生存期为50个月。
Median survival for node positive R(un) patients was 50 months.
到目前为止,这已经导致接受标准治疗的患者的中位生存期约为2〜3年。
So far, this has resulted in a median survival of about 2 to 3 years for patients receiving standard treatment.
The Duke researchers said the median survival for the 61 patients in the trial was 12.5 months, compared with 11.3 months for the“historical control group”.
尽管已经存在治疗方法,但胶质母细胞瘤患者的中位生存期仅为15个月,少于1/20的患者能超过5年。
Even though treatments already exist, the median survival for patients with glioblastoma is only 15 months- fewer than 1 in 20 survive more than 5 years.
The Duke researchers said the median survival for the 61 patients in the trial was 12.5 months, compared with 11.3 months for the“historical control group.”.
低表达免疫抑制剂组的中位生存期为37个月,高表达组为20个月,表明免疫对总体生存有潜在影响。
Those with low-expression of immune inhibitors had a median survival of 37 months versus 20 months for the high-expression group, indicating potential immune impact on overall survival..
患者的中位生存时间只有4~6个月。
Median survival for patients is only four to six months.
脑转移的存在通常会使患者的中位生存期缩短至不到8个月7。
The presence of brain metastases often reduces median survival to less than 8 months.
中文
Bahasa indonesia
日本語
عربى
Български
বাংলা
Český
Dansk
Deutsch
Ελληνικά
Español
Suomi
Français
עִברִית
हिंदी
Hrvatski
Magyar
Italiano
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Nederlands
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt